March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...

Xenon plans to submit a new drug application for azetukalner to the U.S. Food and Drug Administration for the treatment of focal onset seizures in the third quarter of 2026. ・CEO Ian Mortimer said ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

Xenon Pharmaceuticals Inc. XENE shares are up during Monday’s premarket session following the announcement of positive ...

Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, ...

Xenon Pharmaceuticals released positive topline results from a phase three study of its azetukalner drug for focal onset seizures. The study met its primary endpoint for median percent change in ...

Xenon Pharmaceuticals (XENE) stock soared 40% after Phase 3 trial data for azetukalner exceeded expectations in focal onset seizures. FDA filing set for Q3 2026.

Late-onset epilepsy (LOE) may represent a distinctive neurodegenerative-linked epilepsy subtype, with new data showing that individuals who develop epilepsy after midlife have substantially greater ...

An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.

Patients can spend anywhere from several days to several weeks in an epilepsy monitoring unit with electrodes protruding from holes drilled in their skulls. This is intracranial EEG, and it is now ...